Price movement over the last 24 hours
ADMA Biologics Inc vs Caterpillar Inc — how do they compare? ADMA Biologics Inc trades at $9.28 (market cap $2.13B), while Caterpillar Inc trades at $948.77 (market cap $433.01B). The key difference: Caterpillar Inc is far larger — about 203.3× ADMA Biologics Inc's market cap, and Caterpillar Inc pays a 0.69% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | CAT | |
|---|---|---|
Market Cap | $2.13B | $433.01B |
Sector | Health | Industrials |
52-Week High | $20.38 | $1.06K |
52-Week Low | $7.60 | $394.29 |
Enterprise Value | $2.20B | $472.01B |
Dividend Yield | — | 0.69% |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Caterpillar (CAT) trades at $969.92, up 0.66% on the day and near its 52-week high, supported by strong earnings beats and bullish technical signals. The stock's valuation multiples are elevated with a P/E of 48.3 and P/S of 6.44, but robust profitability metrics like a 51.35% ROE and consistent dividend growth underscore fundamental strength. Recent news highlights CAT's exposure to AI-driven infrastructure demand, with the Power & Energy segment emerging as a key growth driver amid a record backlog.
Outlook remains positive given earnings momentum and analyst consensus, though high valuation and macroeconomic sensitivity pose risks. The stock offers growth from data center and infrastructure trends, but investors should weigh premium pricing against potential cyclical headwinds in industrial markets.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →Caterpillar Inc. designs, manufactures, and markets construction, mining, and forestry machinery. The Company also manufactures engines and other related parts for its equipment, and offers financing and insurance. Caterpillar distributes its products through a worldwide organization of dealers.
Read more on CAT →